Suppr超能文献

Ⅰ期非小细胞肺癌立体定向体部放疗后预处理 FDG 摄取与局部控制的关系:初步结果。

Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results.

机构信息

Department of Radiology, Shikoku Cancer Center, Kou-160, Minamiumemoto-Machi, Matsuyama, Ehime 791-0280, Japan.

出版信息

Jpn J Clin Oncol. 2011 Apr;41(4):543-7. doi: 10.1093/jjco/hyq249. Epub 2011 Jan 24.

Abstract

OBJECTIVE

Relationship between pretreatment uptake of (18)F-fluoro-2-deoxy-d-glucose and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer was examined.

METHODS

Between June 2006 and June 2009, 90 clinically diagnosed stage I primary lung cancer in 86 patients were treated with stereotactic body radiotherapy in Shikoku Cancer Center. Among these, 51 tumors in 51 patients were evaluated by positron emission tomography using (18)F-fluoro-2-deoxy-d-glucose before treatment. Twenty-six tumors of histopathologically confirmed non-small-cell lung cancer were reviewed in this study. Tumors were divided into two groups by the threshold maximum standardized uptake value of 5.0 (high-uptake tumors, 9; low-uptake tumors, 17). One tumor with low uptake was pure ground-glass opacity. Typically, 48 Gy in four fractions was given at the isocenter.

RESULTS

Follow-up time was 4-44 months (median, 21 months). Local failure-free rates at 15 months of the high-uptake group and the low-uptake group were 40% and 93% for all tumors (P= 0.0001), 0% and 91% for tumors 3 cm or less (P= 0.0004), 50% and 100% for tumors larger than 3 cm, and 40% and 89% for the mainly solid tumors (P= 0.0010). There were no statistically significant differences of local failure-free rates according to age, sex and tumor size (P= 0.4804, P= 0.4170 and P= 0.3638, respectively).

CONCLUSIONS

High uptake of (18)F-fluoro-2-deoxy-d-glucose in a primary tumor was the significant unfavorable factor for local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer.

摘要

目的

研究Ⅰ期非小细胞肺癌患者立体定向体部放疗前(18)F-氟代脱氧葡萄糖摄取与局部控制的关系。

方法

2006 年 6 月至 2009 年 6 月,在四国癌症中心对 86 例临床诊断为Ⅰ期原发性肺癌的患者进行了立体定向体部放疗。其中,51 例患者的 51 个肿瘤在治疗前通过(18)F-氟代脱氧葡萄糖进行了正电子发射断层扫描评估。在这项研究中,回顾了 26 个经组织病理学证实为非小细胞肺癌的肿瘤。根据 5.0 的最大标准化摄取阈值,将肿瘤分为两组(高摄取肿瘤 9 个,低摄取肿瘤 17 个)。一个摄取值低的肿瘤是纯磨玻璃样混浊。通常,在等中心点给予 48 Gy 的 4 次分割。

结果

随访时间为 4-44 个月(中位数 21 个月)。高摄取组和低摄取组的所有肿瘤局部无复发生存率在 15 个月时分别为 40%和 93%(P=0.0001),肿瘤直径 3cm 或以下时分别为 0%和 91%(P=0.0004),肿瘤直径大于 3cm 时分别为 50%和 100%,主要为实体瘤时分别为 40%和 89%(P=0.0010)。年龄、性别和肿瘤大小对局部无复发生存率无统计学差异(P=0.4804、P=0.4170 和 P=0.3638)。

结论

Ⅰ期非小细胞肺癌患者立体定向体部放疗前原发肿瘤摄取(18)F-氟代脱氧葡萄糖高是局部控制的显著不利因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验